Full Press Release Details
Supernus Enters Into $150 Million Credit Facility
MD, February 14, 2023 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company
focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it
entered into a credit line agreement (the "Credit Line") with UBS Bank USA ("UBS") providing the Company an
uncommitted demand secured line of credit of up to $150 million, which can be drawn at any time.
Any fixed rate borrowing will bear interest at
a fixed interest rate, equal to the sum of the UBS Fixed Funding Rate plus the applicable Percentage Spread established in the Credit
Line. Any variable rate borrowing will bear interest at a variable interest rate, equal to the sum of the UBS Variable Rate plus the applicable
Percentage Spread established in the Credit Line.
"We are pleased to further enhance the strength
and flexibility of our balance sheet with this line of credit," said Jack Khattar, President and CEO.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved
treatments for epilepsy, migraine, ADHD, hypomobility in PD, cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving
levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. We are developing a broad range of novel CNS product
candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but
relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to
risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition
to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability
to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy;
the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures;
the Company's ability to increase the number of prescriptions written for each of its products; the Company's ability to increase
its net revenue; the Company's ability to commercialize its products including Qelbree; the Company's ability to enter into
future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's
product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures;
the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's
product candidates; the Company's ability to protect its intellectual property and operate its business without infringing upon
the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements;
the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates
of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase
its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the
Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; the Company's
ability to increase the number of prescriptions written for each of its products and the products of Adamas; the Company's ability
to increase its net revenue from its products and the products of Adamas; and other risk factors set forth from time to time in the Company's
filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934,
as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after
the date hereof or to reflect the occurrence of anticipated or unanticipated events.
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com